Your browser doesn't support javascript.
loading
Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
Miskowiak, Kamilla W; Obel, Zacharias K; Guglielmo, Riccardo; Bonnin, Caterina Del Mar; Bowie, Christopher R; Balanzá-Martínez, Vicent; Burdick, Katherine E; Carvalho, Andre F; Dols, Annemieke; Douglas, Katie; Gallagher, Peter; Kessing, Lars V; Lafer, Beny; Lewandowski, Kathryn E; López-Jaramillo, Carlos; Martinez-Aran, Anabel; McIntyre, Roger S; Porter, Richard J; Purdon, Scot E; Schaffer, Ayal; Stokes, Paul R A; Sumiyoshi, Tomiki; Torres, Ivan J; Van Rheenen, Tamsyn E; Yatham, Lakshmi N; Young, Allan H; Vieta, Eduard; Hasler, Gregor.
Afiliación
  • Miskowiak KW; Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Department of Psychology, University of Copenhagen | Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.
  • Obel ZK; Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
  • Guglielmo R; Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Department of Psychology, University of Copenhagen | Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.
  • Bonnin CDM; Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
  • Bowie CR; Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland.
  • Balanzá-Martínez V; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy.
  • Burdick KE; Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
  • Carvalho AF; Department of Psychology, Queen's University, Kingston, Canada.
  • Dols A; Department of Medicine, University of Valencia, Valencia, Spain.
  • Douglas K; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Gallagher P; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Kessing LV; IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment), Deakin University, Geelong, Victoria, Australia.
  • Lafer B; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Lewandowski KE; Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
  • López-Jaramillo C; Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
  • Martinez-Aran A; Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
  • McIntyre RS; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Porter RJ; Bipolar Disorder Research Program, Institute of Psychiatry, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Purdon SE; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Schaffer A; McLean Hospital, Schizophrenia and Bipolar Disorder Program, Belmont, Massachusetts, USA.
  • Stokes PRA; Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia.
  • Sumiyoshi T; Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
  • Torres IJ; Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada.
  • Van Rheenen TE; Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
  • Yatham LN; Department of Psychiatry, University of Alberta, Edmonton, Canada.
  • Young AH; Department of Psychiatry, University of Toronto, Toronto, Canada.
  • Vieta E; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Hasler G; Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
Bipolar Disord ; 26(3): 216-239, 2024 May.
Article en En | MEDLINE | ID: mdl-38433530
ABSTRACT

BACKGROUND:

Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD.

METHODS:

We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials.

RESULTS:

Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias.

CONCLUSIONS:

Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Trastorno Bipolar / Disfunción Cognitiva / Estimulantes del Sistema Nervioso Central Límite: Humans Idioma: En Revista: Bipolar Disord Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Trastorno Bipolar / Disfunción Cognitiva / Estimulantes del Sistema Nervioso Central Límite: Humans Idioma: En Revista: Bipolar Disord Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Dinamarca